Targets › FOXP3
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.
Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. (UniProt, Q9BZS1)
Open in Phaseline: the race on FOXP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rafael Correa-Rocha | Autologous thyTreg Regulatory T cells differentiated from thymic tissue, expanded and stimulated with IL-2 | FOXP3 | Phase 1 | Heart Transplantation | Dec 2026 |
Heart Transplantation (1)
other (1)
Rafael Correa-Rocha (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.